ProMIS Neurosciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

NET LOSS PER SHARE

NET LOSS PER SHARE

9 Months Ended

Sep. 30, 2022

NET LOSS PER SHARE

NET LOSS PER SHARE

14.

NET LOSS PER SHARE

The following table sets forth the computation of basic and diluted net loss per share attributable to common shareholders:


	Nine Months Ended September 30,
	2022		2021
Numerator:
Net loss attributable to common shareholders	$	10,879,155	$	7,648,055
Denominator:
Weighted-average shares outstanding used in computing net loss per share attributable to common shareholders, basic and diluted		7,195,529		5,310,483
Net loss per share attributable to common shareholders, basic and diluted	$	(1.51)	$	(1.44)

The following outstanding potentially dilutive Common Shares equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive:


	September 30,
	2022		2021
Options issued and outstanding under stock option plan		1,043,025		689,321
Warrants		1,458,496		1,560,588
Convertible debt		—		1,166,667
Series 1 Convertible Preferred Shares		1,166,667		—
Deferred share units		1,061		1,061
Total		3,669,249		3,417,637